Timeline
2019
2020
- Langen Junior Science Award
- WHO Declares Pandemic
- Paul Ehrlich and Ludwig Darmstaedter Prize
- Supply Bottleneck for Pneumococcal Vaccines
- Blood Donation Remains Possible
- Convalescent Plasma: First Clinical Trial
- COVID-19 Vaccines: First Clinical Trial
- Marketing Authorisation of Gene Therapy
- COVID-19 Vaccines: Second Clinical Trial Approved
- German Presidency of the EU Council
- COVID-19 Vaccines: Two Clinical Trials Approved
- Another Clinical Trial Approved
- Start of Two Rolling Review Procedures
- Allergen Products: European Standards
- Allergen Product: First European Marketing Authorisation
- COVID-19 Peptide Vaccine: First Clinical Trial
- COVID-19 Vaccine: Third Rolling Review Procedure
- Validation of COVID-19 Rapid Tests
- First Marketing Authorisation of a COVID-19 Vaccine
- SafeVac App Available
In June 2019, the European Commission grants marketing authorisation to an Ebola vaccine for the first time. The Paul-Ehrlich-Institut supported the development of the Ebola vaccine, from clinical trials by way of marketing authorisation through to batch testing. Based on this data, WHO prequalifies the vaccine in November 2019. This prequalification is an important prerequisite for the use of the vaccine in countries most at risk of Ebola outbreaks. The Ebola vaccine has already been used successfully in the Congo.